Thank you for your questions.
My understanding is that you had two parts to this. Number one is what would be required from a funding point of view to support the work. Number two is the issue about the Ritalin and the sampling.
I think the most important thing is to first of all get some good data. There are two elements to that. One is prescription monitoring programs. There's a lot of good work being done in each province, but requiring and encouraging each province and territory to have a way of monitoring what is being prescribed, what is being dispensed, and who is being prescribed medications is critical.
Also, I think we need to learn from each other about initiatives being done in various locations, so that we don't redo and replicate work that has already been done. Creating a network of information regarding prescription monitoring programs is key, I think. That will allow us to mine that data so that we can look at national trends as well as identify the prevalence of medications like Ritalin. Until we have some information on concrete data, it's really difficult to look at why it's occurring when we don't even know how much it is occurring across a province and across the country.